Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2016
March 2016, Vol 6, No 3
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Prostate Cancer
Charles Bankhead
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study (Friedenreich CM, et al.
Eur Urol
. 2016 Jan 7. Epub ahead of print). Men with the highest self-reported levels of physical activity had a >40% reduction in the risk for overall mortality from prostate cancer. High levels of recreational activity were associated with a similar reduction in prostate cancer–specific mortality. Higher sustained levels of recreational activity before and after a prostate cancer diagnosis predicted lower all-cause mortality, suggest Christine M. Friedenreich, PhD, Scientific Leader of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Canada, and colleagues. “The big news here is that physical activity post-diagnosis improves survival…This paper is a good news story for men who have been diagnosed with prostate cancer since increasing their levels of activity after diagnosis can improve their survival,” said Dr Friedenreich.
Modifiable Risk Factors
Despite the large number of men affected by prostate cancer annually, potentially modifiable risk factors have received relatively little attention in the literature. Many recent studies have focused on dietary factors and obesity, and their potential contributions to prostate cancer risk. By comparison, the association between physical activity and prostate cancer has received little attention, particularly the impact of physical activity on the mortality of men with this disease, according to Dr Friedenreich and colleagues. To examine physical activity and mortality in patients with prostate cancer, the investigators analyzed self-reported data provided by 830 men newly diagnosed with stage II to stage IV prostate cancer between 1997 and 2000. Each man reported his estimated activity level at diagnosis and at as many as 3 follow-up visits after diagnosis. The self-reported information was converted into the annual amount of metabolic equivalents (METs) of activity weekly. (A MET is defined as the ratio of the energy rate expended during an activity to the energy rate expended at rest.) All participants survived at least 2 years after diagnosis, and the cohort had a maximum follow-up of 17 years. During follow-up, 458 of the patients died, of whom 170 men died from prostate cancer. In addition, 239 of the patients had disease recurrence or progression after the first follow-up visit.
Significant Impact of Physical Activity
Comparing self-reported physical activity and prostate cancer mortality, the investigators found that men who had a postdiagnosis activity level of >119 METs (ie, the highest activity category) had a lower mortality risk than men whose activity level was ≤42 METs (ie, the lowest category), a significant difference (hazard ratio [HR], 0.58;
P
<.01). A separate analysis that focused specifically on recreational activity, defined as any exercise or sport performed standing up, yielded a similar difference for prostate cancer–specific mortality. The analysis showed that men in the highest category of recreational activity (≥26 METs) had a significantly lower mortality risk from prostate cancer than men who reported the least recreational activity (≤4 METs; HR, 0.56;
P
<.01). An analysis of physical activity before and after receiving a diagnosis of prostate cancer yielded a significant reduction in all-cause mortality for men who maintained high levels of recreational activity versus men with the least recreational activity. Men who had sustained recreational activity of >18 to 20 METs had a lower risk for all-cause mortality than men who had sustained recreational activity of less than 7 to 8 METs (HR, 0.66). “These findings support emerging recommendations to increase physical activity after the diagnosis of PCa [prostate cancer] and would inform a future exercise intervention training examining PCa outcomes,” the investigators noted.
Related Articles
Darolutamide Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer
By
Anne Rowe
March 2023, Vol 13, No 3
ASCO GU 2023 Highlights
,
Prostate Cancer
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
By
Patricia Stewart
July 2022, Vol 12, No 7
Prostate Cancer
Abiraterone Added to ADT Improves Survival in Patients with High-Risk Prostate Cancer
By
Patricia Stewart
January 2022, Vol 12, No 1
Prostate Cancer
Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
Interview with the Innovators – December 2021
Interview with the Innovators
,
Prostate Cancer
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes